Curative Effect of Sintilimab Combined with Bevacizumab and Changes of Serum VEGF and MMP-9 in Patients with Unresectable Hepatocellular Carcinoma
Objective To explore the curative effect of sintilimab combined with bevacizumab and changes of serum vascular endothelial growth factor(VEGF)and matrix metalloproteinase-9(MMP-9)in patients with unresectable hepatocellular carcinoma(HCC).Methods A total of 80 patients with unresectable HCC confirmed in Zhoukou Central Hospital were enrolled between January 2021 and December 2022.According to treatment methods,they were divided into control group and combination group.Control group received oral sorafenib toluene sulfonate treatment,including 36 cases.The combined group received sindilizumab combined with bevacizumab,and 44 cases were included.The disease control rates and objective remission rates in the two groups were recorded after 4 cycles of treatment.The changes of serum VEGF and MMP-9 before treatment and after 2 and after 4 cycles of treatment,and the occurrence of side effects during treatment were compared between the two groups.After 6-30 months of follow-up,survival curves were drawn to compare median overall survival(OS)and median progression-free survival(PFS)between the two groups.Results There were significant differences in disease control rate and objective remission rate between combination group and control group(77.27％vs 44.44％,25.00％vs 5.56％,P＜0.05).After treatment,levels of serum VEGF and MMP-9 were decreased in combination group,and which were lower than those in control group(P＜0.05).The differences in incidence of hypothyroidism between combination group and control group were statistically significant(18.18％vs 2.78％,P＜0.05).The difference in incidence of alopecia and hand foot syndrome between combination group and control group was statistically significant(0 vs 22.22％,0 vs 27.78％,P＜0.05).The median follow-up time for all patients was 18 months.The median OS and PFS in combination group were 16.9 months and 4.8 months,which in control group were 10.5 months and 3 months,and the difference between the two groups was statistically significant(P＜0.05).Conclusion Sintilimab combined with bevacizumab can better control disease development in patients with unresectable HCC,significantly reduce levels of serum tumor-related factors and increase survival rate,with good safety.
万方数据
维普
